+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Gene Therapy Collaboration and Licensing Deals 2016-2023

  • PDF Icon


  • 450 Pages
  • November 2023
  • Region: Global
  • CurrentPartnering
  • ID: 4495780
Gene Therapy Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the gene therapy deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of gene therapy deals from 2016 to 2023.

The report provides a detailed understanding and analysis of how and why companies enter gene therapy deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

The report includes collaboration, development, research and licensing deals.

This report contains a comprehensive listing of 688 gene therapy deals announced since 2016 including financial terms where available including links to online deal records of actual gene therapy partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of gene therapy dealmaking.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in gene therapy dealmaking since 2016.

Chapter 3 provides an overview of the leading gene therapy deals since 2016. Deals are listed by headline value.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in gene therapy dealmaking with a brief summary followed by a comprehensive listing of gene therapy deals, as well as contract documents available in the public domain.

Chapter 5 provides a comprehensive and detailed review of gene therapy deals signed and announced since Jan 2016, where a contract document is available in the public domain.

Chapter 6 provides a comprehensive and detailed review of gene therapy partnering deals signed and announced since Jan 2016. The chapter is organized by specific gene therapy technology type in focus.

The report also includes numerous table and figures that illustrate the trends and activities in gene therapy deal making since 2016.

In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Gene Therapy Collaboration and Licensing Deals provides the reader with the following key benefits:

• Understand deal trends since 2016
• Browse gene therapy collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, deal type and therapy area
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

Gene Therapy Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of gene therapy trends and structure of deals entered into by leading biopharma companies worldwide.

Gene Therapy Collaboration and Licensing Deals includes:

• Trends in gene therapy dealmaking in the biopharma industry
• Directory of gene therapy deal records covering pharmaceutical and biotechnology
• The leading gene therapy deals by value
• Most active gene therapy licensing dealmakers
Gene Therapy Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive SummaryChapter 1 - Introduction
Chapter 2 - Trends in gene therapy dealmaking
2.1. Introduction
2.2. Gene therapy deals over the years
2.3. Most active gene therapy dealmakers
2.4. Gene therapy deals by deal type
2.5. Gene therapy deals by therapy area
2.6. Gene therapy deals by industry sector
2.7. Deal terms for gene therapy deals
2.7.1 Gene therapy deals headline values
2.7.2 Gene therapy deal upfront payments
2.7.3 Gene therapy deal milestone payments
2.7.4 Gene therapy royalty rates
Chapter 3 - Leading gene therapy deals
3.1. Introduction
3.2. Top gene therapy deals by value
Chapter 4 - Most active gene therapy dealmakers
4.1. Introduction
4.2. Most active gene therapy dealmakers
4.3. Most active gene therapy deals company profiles
Chapter 5 - Gene therapy contracts dealmaking directory
5.1. Introduction
5.2. Gene therapy contracts dealmaking directory
Chapter 6 - Gene therapy dealmaking by technology type
Deal directory
Deal directory - Gene therapy deals by company A-Z
Deal directory - Gene therapy deals by deal type
Deal directory - Gene therapy deals by therapy area
Deal type definitions
Table of figures
Figure 1: Gene therapy deals since 2016
Figure 2: Active gene therapy dealmaking activity - 2016 - 2023
Figure 3: Gene therapy deals by deal type since 2016
Figure 4: Gene therapy deals by therapy area since 2016
Figure 5: Gene therapy deals by industry sector since 2016
Figure 6: Gene therapy deals with a headline value
Figure 7: Gene therapy deals with an upfront value
Figure 8: Gene therapy deals with a milestone value
Figure 9: Gene therapy deals with a royalty rate value
Figure 10: Top gene therapy deals by value since 2016
Figure 11: Most active gene therapy dealmakers 2016 - 2023
Figure 12: Gene therapy deals by technology type since 2016

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • 2seventy bio
  • 4D Molecular Therapeutics
  • AavantiBio
  • AAVLife
  • AAVnerGene
  • Abbvie
  • Abby Grace Foundation
  • Abeona Therapeutics
  • Ablynx
  • Accelerator for Technological Research in Genomic Therapies
  • Accenture
  • ACGT
  • Actinium Pharmaceuticals
  • Adaptimmune
  • Addex Therapeutics
  • Advanced BioScience Laboratories
  • Advanced Biotherapeutics Consulting
  • AdVec
  • Aevitas Therapeutics
  • Affinia Therapeutics
  • AffyXell Therapeutics
  • Agathos Biologics
  • Agensys
  • AgeX Therapeutics
  • Agilis Biotherapeutics
  • Agrivida
  • AGTC
  • AH Diagnostics
  • Akouos
  • Alcyone Lifesciences
  • Alder Biopharmaceuticals
  • Aldevron
  • Allegheny General Hospital
  • Allen Institute for Brain Science
  • Allergan
  • Alliance for Cancer Gene Therapy
  • Alliance for Regenerative Medicine
  • Allogene Therapeutics
  • AllStripes
  • Almirall
  • Alnylam Pharmaceuticals
  • ALS Finding a Cure Foundation
  • ALS Therapy Development Institute
  • Amarantus BioSciences
  • Amarna Therapeutics
  • Ambys Medicines
  • American Association of Neuromuscular & Electrodiagnostic Medicine
  • American Gene Technologies
  • American Society of Gene and Cell Therapy
  • AmerisourceBergen
  • Amgen
  • Amicus Therapeutics
  • AmorChem
  • Amplimmune
  • Amsterdam Molecular Therapeutics
  • AnC Bio
  • AnGes MG
  • Angionetics
  • Annapurna Therapeutics
  • Apceth
  • Apollo Therapeutics
  • Applied DNA Sciences
  • Applied StemCell
  • Arbor Biotechnologies
  • ARCA Biopharma
  • Ariad Pharmaceuticals
  • Ark Therapeutics
  • Arranta Bio
  • Aruvant Sciences
  • Ascenion
  • ASC Therapeutics
  • Asklepios Biopharmaceutical
  • Astellas Pharma
  • Auburn University
  • Audentes Therapeutics
  • Autolomous
  • Avacta
  • Avalanche Biotechnologies
  • Avectas
  • Avellino Labs
  • AveXis
  • Avila Therapeutics
  • Avita Therapeutics
  • Avrobio
  • Avvinity Therapeutics
  • Axovant Gene Therapies
  • Axxam
  • Bachmann-Strauss Dystonia & Parkinson Foundation
  • Baxter International
  • Bayer
  • Baylor College
  • Baylor College of Medicine
  • B Braun
  • B Braun CeGaT
  • Beam Therapeutics
  • Beijing Genomics Institute (BGI)
  • Bellicum Pharmaceuticals
  • Benitec Biopharma
  • Be The Match BioTherapies
  • BIA Separations
  • Bill and Melinda Gates Foundation
  • Bio-Fortune
  • Bio-Techne
  • BioCentriq
  • BioCure
  • Biogen
  • BioLife Solutions
  • BioMarin Pharmaceutical
  • BioMetrx
  • Bionic Sight
  • BioSante Pharmaceuticals
  • BioSpherix
  • Biotechnology and Biological Sciences Research Council (BBSRC)
  • Bioverativ
  • Blackstone
  • Blood Centers of America
  • Blood Systems Research Institute
  • Bluebird Bio
  • Blueprint Genetics
  • Boehringer Ingelheim
  • Bpifrance
  • Brain Research Through Advancing Innovative NeurotechnologiesInitiative
  • Brammer Bio
  • BridgeBio Pharma
  • Bristol-Myers Squibb
  • Broad Institute
  • Brooklyn ImmunoTherapeutics
  • Butantan Institute
  • California Institute for Regenerative Medicine
  • Calimmune
  • Calyxt
  • CAMP4 Therapeutics
  • CANbridge Pharmaceuticals
  • Cangene
  • Capsida Biotherapeutics
  • Casebia Therapeutics
  • Case Western Reserve University
  • Case Western Reserve University School of Medicine
  • Castle Creek Biosciences
  • Catalent


  • The publisher reports provide insight into the trends and terms of partnering deals in the global life sciences sector.
  • The publisher reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.
  • The publisher analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.
  • The publisher reports source deal data from our proprietary deals and alliances database. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal.
  • The data in the deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.

The publisher provides comprehensive coverage of the following partnering or deal types:

  • Asset purchase
  • Assignment
  • Co-development
  • Co-market
  • Co-promotion
  • Collaborative R&D
  • Contract service
  • Cross-licensing
  • Development
  • Distribution
  • Equity purchase
  • Evaluation
  • Grant
  • Joint venture
  • Licensing
  • Loan
  • Manufacturing
  • Marketing
  • Option
  • Promotion
  • Research
  • Royalty financing
  • Settlement
  • Spin out
  • Sub license
  • Supply
  • Termination
  • Warrant

Every deal record is fully categorized and includes the following data, where available:

  • Industry sector
  • Therapy areas
  • Technology type
  • Deal components
  • Financial terms
  • Stage of development
  • Exclusivity
  • Asset type
  • Geographic focus
  • Excluded geography
  • Company press release
  • SEC filing data including contract document

All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.